PD-L1 表达与亚洲和西方胃癌患者的总生存期。
PD-L1 expression and overall survival in Asian and western patients with gastric cancer.
机构信息
Yonsei Cancer Center, Yonsei University Health System, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea.
Songdang Institute for Cancer Research, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea.
出版信息
Future Oncol. 2022 Jul;18(21):2623-2634. doi: 10.2217/fon-2022-0103. Epub 2022 May 26.
Data are limited on PD-L1 expression and its association with overall survival (OS) in gastric cancer (GC) patients receiving routine care in different regions. In a retrospective study, PD-L1 expression was assayed using the 22C3 pharmDx on GC tumor samples collected between 2003 and 2017 at South Korean and US cancer centers. PD-L1 positivity was defined as combined positive score (CPS) ≥1. The relationship between PD-L1 and OS was analyzed. Of 574 GC tumor samples, 67.4% were CPS ≥1 (68.7% in Korean and 65.7% in US patients). PD-L1 expression was not associated with OS (adjusted hazard ratio: 0.94; 95% CI: 0.75-1.17). PD-L1 prevalence and its association with OS was similar between South Korean and US GC patients.
关于在不同地区接受常规治疗的胃癌（GC）患者的 PD-L1 表达及其与总生存期（OS）的关系，数据有限。在一项回顾性研究中，使用 22C3 pharmDx 在 2003 年至 2017 年间于韩国和美国癌症中心收集的 GC 肿瘤样本中检测了 PD-L1 表达。PD-L1 阳性定义为联合阳性评分（CPS）≥1。分析了 PD-L1 与 OS 的关系。在 574 例 GC 肿瘤样本中，67.4%的 CPS≥1（韩国患者为 68.7%，美国患者为 65.7%）。PD-L1 表达与 OS 无关（调整后的危险比：0.94；95%CI：0.75-1.17）。韩国和美国 GC 患者的 PD-L1 患病率及其与 OS 的关系相似。
Zotero 插件